Skip to main content

Ewing Sarcoma Outcomes in a Country with Limited Resources: Egypt as an Example

Research Authors
Ahmed Mohammed Morsy1 , Salah Abdel-Hadi2 , Khalid Mohammed Rezk3 ,Gamal Amira4 , Badawy Mohammed Ahmed3 , Marwa Tammam Hussien5 , Mahmoud Gamal Ameen5 , Hosam Eldein Mostafa Kamel6 , Doaa Mohamed Fouad6 , Alia Mohamed Attia7 , Asmaa Salah7 , Osama Mostaf
Research Date
Research Journal
American Journal of Cancer Research
Research Publisher
e-century Publishing Corporation
Research Rank
Original Article
Research Vol
Am J Cancer Res 2021;11(6)
Research Website
www.ajcr.us/ISSN:2156-6976/ajcr0133352
Research Year
2021
Research_Pages
3212-3226
Research Abstract

Abstract
Background
Scarcity of published research that comprehensively and meticulously analyzed the patient, disease, and treatment factors of prognostic significance in Ewing sarcoma (EWS) in Egypt.
Aim
To assess survival outcomes of EWS in Upper Egypt, delineating factors of prognostic significance in comparison to other leading oncology centers in Egypt and internationally.
Methods
We retrospectively reviewed medical records of 85 patients with a verified diagnosis of EWS at Pediatric Oncology department and Medical Oncology department at South Egypt Cancer Institute to gather data relevant to the patient, disease, and treatment variables of the study in the period from 2001 to 2015. Survival was estimated using the Kaplan Meier method and differences between various groups were determined by log rank test. Univariable and multivariable analyses were performed using Cox regression.
Results
With a median follow-up period of 62.7 months (95CI% 52.2-73.2, SE= 5.4) for the study patients, the estimates of event-free survival (EFS) and overall survival (OS) at 3 and 5 years were 42.1% and 50.6%, and 40.8% and 48.5%, respectively. Metastatic disease at initial presentation (HR=8.91, 95%CI, 4.00-19.9; P< 0.0001) stood as the most powerful predictor of OS in the multivariable analysis, followed by surgery used as a local modality (HR=0.16, 95%CI, 0.06-0.44; P= 0.0004). Response to neoadjuvant chemotherapy (HR=2.61, 95%CI, 1.11-6.13; P= 0.028), primary tumor size (HR=2.49, 95%CI, 1.03-6.03; P= 0.044) were also shown to be significantly associated with OS. Radiotherapy as a local modality, whose effect, apparently shown to increase the hazard of events occurrence in the univariable analysis, an effect that was reversed to reveal EFS advantage (HR=0.41, 95%CI, 0.18-0.95; P= 0.036) after control of other variables.
Conclusion
With 5-year OS of 48.5%, our survival results were comparable to those previously published from Egypt; however, differences still exist between centers due to varied representative study samples. However, outcomes in Egypt in general are still inferior to internationally published studies